AleraCare and PURE Healthcare Announce Intent to Merge
The proposed merger creates an unprecedented opportunity to provide high-quality patient care, improve clinical outcomes and enhance the availability of infusion services that lower the overall cost to the healthcare system overall.
Founded in 2019, AleraCare's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. Administered at convenient, accessible, patient-first locations, AleraCare is focused on maintaining trusted-partner status with physicians, payors, drug distributors and pharmaceutical manufacturers. The company has rapidly expanded to over 30 ambulatory infusion centers across the country and is a provider-of-choice for infusion services to high-need and medically complex populations.
Pure Healthcare, founded in 2018, is on a mission to transform the healthcare industry by making infusion therapy more affordable and accessible—while delivering a personalized, patient-centered experience. Pure specializes in treating chronic and autoimmune conditions such as Alzheimer's disease, multiple sclerosis, and rheumatoid arthritis, offering innovative, high-quality care tailored to individual needs. Its flagship offering, Pure Infusion Suites, has expanded to 43 locations across 14 states. These state-of-the-art suites prioritize patient comfort with private rooms, snacks, and entertainment, all while significantly lowering the cost of infusion services. Pure Healthcare also alleviates the administrative burden for referring providers by supporting patient authorizations and fostering strong partnerships with insurers, ensuring a seamless and efficient care journey from referral to treatment.
The transaction is expected to close in the fourth quarter of 2025, and remains subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
Holland & Knight is serving as legal counsel for AleraCare. Kunzler Bean & Adamson is serving as legal counsel and Cantor Fitzgerald is acting as financial advisor for PURE Healthcare.
About AleraCare
AleraCare is a leading provider of infusion treatments and pharmacy services for high-need and medically complex populations. The company's core lines of business include ambulatory infusion centers, home infusion therapy and specialty pharmacy. AleraCare provides care to patients in over 30 locations across six states throughout the U.S., including Arizona, California, Colorado, Idaho, New Mexico and Utah. For more information, please visit www.aleracare.com.
About PURE Healthcare
Pure Healthcare, founded by BUILD Capital Partners in 2018, is a national medical group dedicated to reducing healthcare costs and improving outcomes for patients with complex chronic and autoimmune conditions like rheumatoid arthritis, Crohn's disease, multiple sclerosis, and Alzheimer's. As a market leader in infusion therapy, Pure Healthcare operates Pure Infusion Suites alongside specialty clinics in rheumatology and neurology, including Memory Treatment Centers and Montana Arthritis Centers. Through strategic payer partnerships, streamlined patient authorizations, and a commitment to personalized, high-quality care, Pure Healthcare delivers scalable value to patients, providers, and payers nationwide. Learn more at www.pureinfusionsuites.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Alpha Cognition Inc. Reports Second Quarter 2025 Financial Results and Provides Operational Update
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG) ('Alpha Cognition' or the 'Company') today announced its financial results for the second quarter ended June 30, 2025. 'The initial ZUNVEYL launch has been met with strong interest from both healthcare providers and patients. Early adoption in nursing homes and by geriatric specialists has created a solid foundation for future growth,' said Michael McFadden, Chief Executive Officer of Alpha Cognition. 'Clinician feedback continues to validate our belief that ZUNVEYL will become an important therapy in the long-term care segment.' Recent Business and Operational Highlights Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Received positive clinician feedback highlighting ZUNVEYL's impact on cognitive function, behavioral symptoms, and its safety profile. Secured the Company's first national Medicare Part D contract with no prior authorization required, ahead of schedule. Sales team engaged with more than 3,700 healthcare professionals and generated prescriptions in over 300 nursing homes. Concluded the Bomb Blast Study, demonstrating that ALPHA-1062 reduced neuroinflammation and neuropathology associated with blast trauma. Second Quarter 2025 Financial Results: ZUNVEYL net product revenues of $1.6 million for the quarter ended June 30, 2025. Research and development expenses for the three months ended June 30, 2025 were $317 thousand compared to $967 thousand for the same period in 2024. Selling, general and administrative expenses for the three months ended June 30, 2025 were $6.5 million compared to $1.4 million for the same period in 2024, driven primarily by commercial-readiness activities. Net operating loss for the three months ended June 30, 2025 were $5.7 million compared to $2.4 million for the same period in 2024. Net loss for the for the three months ended June 30, 2025 were $10.5 million compared to $2.1 million for the same period in 2024, primarily due to a $5.2 million non-cash change in the value of warrant liabilities. Cash and cash equivalents of $39.4 million as of March 31, 2025 compared to $48.6 million as of December 31, 2024. At current utilization rate, the Company expects a cash runway of approximately two years. Following the release, management will host a conference call to review financial and operating results. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury ('mTBI'), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. ZUNVEYL's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. INDICATION AND USAGE ZUNVEYL is a cholinesterase inhibitor indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS ZUNVEYL is contraindicated in patients with known hypersensitivity to benzgalantamine, galantamine, or to any inactive ingredients in ZUNVEYL. Serious skin reactions have occurred. WARNINGS AND PRECAUTIONS Serious Skin Reactions: Serious skin reactions (Stevens-Johnson syndrome and acute generalized exanthematous pustulosis) have been reported in patients receiving galantamine (the active metabolite of ZUNVEYL tablets). If signs or symptoms suggest a serious skin reaction, use of this drug should not be resumed, and alternative therapy should be considered. Anesthesia: See Drug Interactions Section Cardiovascular Conditions: Cholinesterase inhibitors, including ZUNVEYL, have vagotonic effects on the sinoatrial and atrioventricular nodes, leading to bradycardia and AV block. Bradycardia and all types of heart block have been reported in patients taking cholinesterase inhibitors, both with and without known underlying cardiac conduction abnormalities. Therefore, all patients should be considered at risk for adverse effects on cardiac conduction. Patients treated with galantamine up to 24 mg/day using the recommended dosing schedule showed a dose-related increase in risk of syncope. Gastrointestinal Conditions: Cholinesterase inhibitors, including ZUNVEYL, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs). Clinical studies of galantamine have shown no increase, relative to placebo, in the incidence of either peptic ulcer disease or gastrointestinal bleeding. Galantamine has been shown to produce nausea, vomiting, diarrhea, anorexia, and weight loss. Monitor the patient's weight during therapy with ZUNVEYL. Genitourinary Conditions: Although this was not observed in clinical trials with galantamine, cholinesterase inhibitors, including ZUNVEYL, may cause bladder outflow obstruction. Neurological Conditions: Cholinesterase inhibitors are believed to have some potential to cause generalized convulsions. Seizure activity may also be a manifestation of Alzheimer's disease. Patients with Alzheimer's disease should be monitored closely for seizures while taking ZUNVEYL. Pulmonary Conditions: Cholinesterase inhibitors, including ZUNVEYL, should be prescribed with care to patients with a history of severe asthma or obstructive pulmonary disease. Monitor for respiratory adverse reactions. ADVERSE REACTIONS The most common adverse reactions with galantamine tablets (≥5%) were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite. DRUG INTERACTIONS Use with Anticholinergics: Galantamine has the potential to interfere with the activity of anticholinergic medications. Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect is expected when cholinesterase inhibitors are given concurrently with succinylcholine, other cholinesterase inhibitors, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol. USE IN SPECIFIC POPULATIONS Pregnancy: Based on animal data may cause fetal harm. Hepatic Impairment: In patients with moderate hepatic impairment, a decrease in clearance of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with severe hepatic impairment is not recommended. Renal Impairment: In patients with a creatinine clearance of 9 to 59 mL/min, an increase in exposure of galantamine was observed; therefore, a dosage adjustment is recommended. Use of ZUNVEYL in patients with creatinine clearance less than 9 mL/min is not recommended. These are not all of the possible side effects of ZUNVEYL. You can report side effects to the FDA. Visit or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'objective,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'target,' 'seek,' 'contemplate,' 'continue' and 'ongoing,' or the negative of these terms, or other comparable terminology intended to identify statements about the future. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward-looking statements are subject to certain risks, including risks regarding our ability to raise sufficient capital to implement our plans to commercialize ZUNVEYL, risks regarding the efficacy and tolerability of ZUNVEYL, risks related to ongoing regulatory oversight on the safety of ZUNVEYL, risk related to market adoption of ZUNVEYL, risks related to the Company's intellectual property in relation to ZUNVEYL, risks related to the commercial manufacturing, distribution, marketing and sale of ZUNVEYL, risks related to product liability and other risks as described in the Company's filings with Canadian securities regulatory authorities and available at and the Company's filings with the United States Securities and Exchange Commission (the 'SEC'), including those risk factors under the heading 'Risk Factors' in the Company's most recent Annual Report on Form 10-K filed with the SEC on March 31, 2025 and the Company's other filings with the SEC available at These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future, except as required by law.
Yahoo
14 hours ago
- Yahoo
Bessent says Japan 'behind the curve' in monetary tightening, in Bloomberg interview
TOKYO (Reuters) -U.S. Treasury Secretary Scott Bessent said Japan is being late in handling monetary tightening during an interview with Bloomberg Television. Bessent also said that U.S. Treasury yields are feeling the impact of overseas developments, including from Japan and Germany. "There's definitely leakage from — the Japanese have an inflation problem," Bessent said in the interview. Bessent mentioned that he had spoken with Bank of Japan Governor Kazuo Ueda. "My opinion, not his — they're behind the curve. So they're going to be hiking," he added. The U.S. Federal Reserve should lower the policy interest rate at least by 1.5%, Bessent also said, suggesting the central bank execute the rate cut by 50 basis points in September. Sign in to access your portfolio
Business Wire
18 hours ago
- Business Wire
Helen of Troy Limited Announces G. Scott Uzzell Appointed to Become Chief Executive Officer
EL PASO, Texas--(BUSINESS WIRE)--Helen of Troy Limited (NASDAQ: HELE), designer, developer, and worldwide marketer of branded consumer home, outdoor, beauty, and wellness products, today announced that its Board of Directors has appointed G. Scott Uzzell (Scott) as Chief Executive Officer, effective September 1, 2025. Brian Grass, the Company's current interim CEO, will return to his role as Chief Financial Officer. Timothy F. Meeker, Chairman of the Board, stated: 'Following a vigorous, deliberate, and thoughtful executive search, the Board has unanimously determined that G. Scott Uzzell is the right person to lead Helen of Troy and capitalize on the Company's leading consumer brand platform. He is a strategic leader with a strong track record of building and growing consumer brands. We believe he has the ability to bring people together, develop and retain talent, and enrich our culture and values, all while being a strong allocator of capital with sound risk management. Scott has great sensitivity to the needs, wants, and expectations of consumers and has the ability to grasp the spirit of the times. His intimate knowledge of brand building and his ability to unite and engage teams is exactly what Helen of Troy needs as it enters its next chapter to boost product innovation and growth.' Mr. Meeker continued: 'On behalf of the Board, I want to thank Brian Grass and Tracy Scheuerman for their dedicated leadership as interim CEO and CFO. Their discipline and focus have been a source of stability as we continue the work needed to deliver better execution, rebuild innovation, restore growth, and regain investor confidence. I am confident they will assist Scott in making a smooth transition.' Mr. Uzzell commented: 'I am excited to have the opportunity to lead Helen of Troy and continue to develop its distinguished family of highly trusted brands and innovations that delight consumers. I intend to leverage the Company's durable foundation as a purpose-driven innovation leader to serve the needs of consumers and to elevate lives in moments that matter everywhere, every day. I look forward to working with Helen of Troy's talented associates to return the Company to consistent growth and deliver strong value creation for shareholders. I also want to take this opportunity to thank Tim and the Board of Directors for this honor and I am eager to begin partnering with the team to build a successful future for all stakeholders.' Scott most recently served as Corporate Vice President & General Manager of Nike North America and was a member of the Nike, Inc. Executive Leadership Team. Nike North America generates +$21B revenue with +30,000 employees across all aspects of Nike and Jordan Brands. Prior to Nike North America, Scott was President & CEO of Converse, Inc. for four years where he led a turnaround built on new product innovation and marketplace excellence. Scott joined Converse, Inc. from The Coca-Cola Company, where he served as President of the Venturing & Emerging Brands Group (VEB). He led the development of a portfolio of high growth emerging brands including Honest Tea, Body Armor, Health-Ade Kombucha and Fairlife Milk. Under Scott's leadership, VEB successfully identified and invested in trend-forward brands and categories, closing multiple M&A transactions to enhance shareholder value. Scott began his career in sales and marketing for leading consumer goods companies, including Procter & Gamble, Coca-Cola, and Nabisco, before returning to Coca-Cola in 2001 to step into more prominent leadership roles. In addition, Scott serves on the SC Johnson Company Board of Directors. He is also presently a member of the Florida A&M University Board and University of Chicago Booth School Advisory Board. Scott received his B.S. in business from Florida A&M University and his MBA from the University of Chicago Booth School of Business. About Helen of Troy Limited Helen of Troy Limited (NASDAQ: HELE) is a leading global consumer products company offering creative products and solutions for its customers through a diversified portfolio of well-recognized and widely-trusted brands, including OXO, Hydro Flask, Osprey, Vicks, Braun, Honeywell, PUR, Hot Tools, Drybar, Curlsmith, Revlon, and Olive & June. All trademarks herein belong to Helen of Troy Limited (or its subsidiaries) and/or are used under license from their respective licensors. For more information about Helen of Troy, please visit Forward-Looking Statements Certain written and oral statements made by the Company and subsidiaries of the Company may constitute 'forward-looking statements' as defined under the Private Securities Litigation Reform Act of 1995. This includes statements made in this press release, in other filings with the SEC, and in certain other oral and written presentations. Generally, the words 'anticipates', 'assumes', 'believes', 'expects', 'plans', 'may', 'will', 'might', 'would', 'should', 'seeks', 'estimates', 'project', 'predict', 'potential', 'currently', 'continue', 'intends', 'outlook', 'forecasts', 'targets', 'reflects', 'could', and other similar words identify forward-looking statements. All statements that address operating results, events or developments that the Company expects or anticipates may occur in the future, including statements related to sales, expenses, including cost reduction measures, earnings per share results, and statements expressing general expectations about future operating results, are forward-looking statements and are based upon its current expectations and various assumptions. The Company currently believes there is a reasonable basis for these expectations and assumptions, but there can be no assurance that the Company will realize these expectations or that these assumptions will prove correct. Forward-looking statements are only as of the date they are made and are subject to risks, many of which are beyond the Company's control, that could cause them to differ materially from actual results. Accordingly, the Company cautions readers not to place undue reliance on forward-looking statements. The forward-looking statements contained in this press release should be read in conjunction with, and are subject to and qualified by, the risks described in the Company's Form 10-K for the year ended February 28, 2025, and in the Company's other filings with the SEC. Investors are urged to refer to the risk factors referred to above for a description of these risks. Such risks include, among others, the geographic concentration of certain United States ('U.S.') distribution facilities which increases its risk to disruptions that could affect the Company's ability to deliver products in a timely manner, the occurrence of cyber incidents or failure by the Company or its third-party service providers to maintain cybersecurity and the integrity of confidential internal or customer data, a cybersecurity breach, obsolescence or interruptions in the operation of the Company's central global Enterprise Resource Planning systems and other peripheral information systems, the Company's ability to develop and introduce a continuing stream of innovative new products to meet changing consumer preferences, actions taken by large customers that may adversely affect the Company's gross profit and operating results, the Company's dependence on sales to several large customers and the risks associated with any loss of, or substantial decline in, sales to top customers, the Company's dependence on third-party manufacturers, most of which are located in Asia, and any inability to obtain products from such manufacturers or diversify production to other regions or source the same product in multiple regions or implement potential tariff mitigation plans, the Company's ability to deliver products to its customers in a timely manner and according to their fulfillment standards, the risks associated with trade barriers, exchange controls, expropriations, and other risks associated with domestic and foreign operations including uncertainty and business interruptions resulting from political changes and events in the U.S. and abroad, and volatility in the global credit and financial markets and economy, the Company's dependence on the strength of retail economies and vulnerabilities to any prolonged economic downturn, including a downturn from the effects of macroeconomic conditions, any public health crises or similar conditions, risks associated with weather conditions, the duration and severity of the cold and flu season and other related factors, the Company's reliance on its Chief Executive Officer and a limited number of other key senior officers to operate its business, risks associated with the use of licensed trademarks from or to third parties, the Company's ability to execute and realize expected synergies from strategic business initiatives such as acquisitions, including Olive & June, divestitures and global restructuring plans, including Project Pegasus, the risks of significant tariffs or other restrictions continuing to be placed on imports from China, Mexico or Vietnam, including by the new U.S. presidential administration which has promoted and implemented plans to raise tariffs and pursue other trade policies intended to restrict imports, or any retaliatory trade measures taken by China, Mexico or Vietnam, the risks of potential changes in laws and regulations, including environmental, employment and health and safety and tax laws, and the costs and complexities of compliance with such laws, the risks associated with increased focus and expectations on climate change and other sustainability matters, the risks associated with significant changes in or the Company's compliance with regulations, interpretations or product certification requirements, the risks associated with global legal developments regarding privacy and data security that could result in changes to its business practices, penalties, increased cost of operations, or otherwise harm the business, the Company's dependence on whether it is classified as a 'controlled foreign corporation' for U.S. federal income tax purposes which impacts the tax treatment of its non-U.S. income, the risks associated with legislation enacted in Bermuda and Barbados in response to the European Union's review of harmful tax competition and additional focus on compliance with economic substance requirements by Bermuda and Barbados, the risks associated with accounting for tax positions and the resolution of tax disputes, the risks associated with product recalls, product liability and other claims against the Company, and associated financial risks including but not limited to, increased costs of raw materials, energy and transportation, significant additional impairment of the Company's goodwill, indefinite-lived and definite-lived intangible assets or other long-lived assets, risks associated with foreign currency exchange rate fluctuations, the risks to the Company's liquidity or cost of capital which may be materially adversely affected by constraints or changes in the capital and credit markets, interest rates and limitations under its financing arrangements, and projections of product demand, sales and net income, which are highly subjective in nature, and from which future sales and net income could vary by a material amount. The Company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future events or otherwise.
